J&J MedTech signs exclusive distribution deal for CGBio’s bone graft product in Asia

Johnson & Johnson (J&J) MedTech, a global leader in the medical device industry, said it signed an exclusive distribution and promotional agreement with CGBio and its affiliate CG MedTech for the NOVOSIS bone graft product.

Under this agreement, the two companies will work together to improve treatment outcomes for patients undergoing trauma and spinal surgeries. J&J MedTech will have exclusive distribution rights for NOVOSIS in four Asian countries and certain parts of China -- Korea, Taiwan, Thailand, India, Hong Kong, and Macau. However, in the Korean market, J&J MedTech will exclusively supply NOVOSIS Trauma, which is provided by CG MedTech, for trauma-related bone treatments.

NOVOSIS is a bone substitute that incorporates recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with hydroxyapatite ceramic. It is used for treating acute fractures of the upper and lower limbs as well as in spinal fusion surgeries with implants.

The hydroxyapatite ceramic serves as a scaffold to promote new bone formation, and its unique slow-release technology enhances sustained therapeutic effects. To date, NOVOSIS has been used in approximately 100,000 surgeries worldwide.

“With millions of people in the Asia Pacific affected by musculoskeletal conditions, our collaboration with CGBio deepens our commitment to accelerating innovative solutions that elevate the standard of care and improve quality of life,” J&J MedTech Asia Pacific Company Group Chairman Vishnu Kalra said. “J&J MedTech is one of the leading global players in biomaterials solutions that reduce pre-operative planning and surgical times and advance repair and healing times for patients.”

J&J’s global expertise, coupled with CGBio’s groundbreaking advancements, addresses critical gaps in orthopedic care improving surgical precision, expediting recovery, and ultimately enhancing patient outcomes across the region, Karla added.

J&J MedTech North Asia Area Managing Director Oh Jin-yong also said, “Our collaboration with CGBio represents a significant step forward in harnessing the power of Korean innovation to transform orthopedic care in Korea and beyond.“

By integrating CGBio’s technology, the company is not only enhancing surgical protocols but also placing the needs of patients at the center of its efforts, Oh added.

Oh stressed the collaboration shows the company’s dedication to local healthcare advancements and its belief in the transformative power of Korean innovative solutions for patients globally.